Literature DB >> 11832958

Progress and challenges for malaria vaccines.

Thomas L Richie1, Allan Saul.   

Abstract

Malaria causes much physical and economic hardship in tropical regions, particularly in communities where medical care is rudimentary. Should a vaccine be developed, it is the residents of these areas that stand to benefit the most. But the vaccine, which has been promised to be 'just round the corner' for many years, remains elusive. It is important to ask why this is so, when effective vaccines exist for many other infectious diseases. What are the reasons for the slow rate of progress, and what has been learned from the first clinical trials of candidate malaria vaccines? What are the remaining challenges, and what strategies can be pursued to address them?

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11832958     DOI: 10.1038/415694a

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  85 in total

Review 1.  Cytokines in the pathogenesis of and protection against malaria.

Authors:  Iñigo Angulo; Manuel Fresno
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

Review 2.  Vaccines for preventing malaria (SPf66).

Authors:  P Graves; H Gelband
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

3.  Evolutionary dynamics of escape from biomedical intervention.

Authors:  Yoh Iwasa; Franziska Michor; Martin A Nowak
Journal:  Proc Biol Sci       Date:  2003-12-22       Impact factor: 5.349

4.  Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1.

Authors:  Markus S Mueller; Annabelle Renard; Francesca Boato; Denise Vogel; Martin Naegeli; Rinaldo Zurbriggen; John A Robinson; Gerd Pluschke
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

Review 5.  Why do we need to know more about mixed Plasmodium species infections in humans?

Authors:  Peter A Zimmerman; Rajeev K Mehlotra; Laurin J Kasehagen; James W Kazura
Journal:  Trends Parasitol       Date:  2004-09

6.  Transcription status of vaccine candidate genes of Plasmodium falciparum during the hepatic phase of its life cycle.

Authors:  Myriam Bodescot; Olivier Silvie; Anthony Siau; Philippe Refour; Paco Pino; Jean-François Franetich; Laurent Hannoun; Robert Sauerwein; Dominique Mazier
Journal:  Parasitol Res       Date:  2004-02-12       Impact factor: 2.289

7.  Extensive antigenic polymorphism within the repeat sequence of the Plasmodium falciparum merozoite surface protein 1 block 2 is incorporated in a minimal polyvalent immunogen.

Authors:  Kevin K A Tetteh; David R Cavanagh; Patrick Corran; Rosemary Musonda; Jana S McBride; David J Conway
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

Review 8.  Effect of vaccine administration modality on immunogenicity and efficacy.

Authors:  Lu Zhang; Wei Wang; Shixia Wang
Journal:  Expert Rev Vaccines       Date:  2015-08-27       Impact factor: 5.217

9.  Apical membrane antigen 1, a major malaria vaccine candidate, mediates the close attachment of invasive merozoites to host red blood cells.

Authors:  G H Mitchell; A W Thomas; G Margos; A R Dluzewski; L H Bannister
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

10.  CD28 costimulation is required for the expression of T-cell-dependent cell-mediated immunity against blood-stage Plasmodium chabaudi malaria parasites.

Authors:  Thomas Rummel; Joan Batchelder; Patrick Flaherty; GayeLyn LaFleur; Payal Nanavati; James M Burns; William P Weidanz
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.